RNS-response-based 'nervous vascular unit' regulation and control targeted liposome drug delivery system and preparation method and application thereof

A technology targeting liposomes and drug delivery systems, applied in the field of anti-ischemic stroke, can solve problems such as disappointment, achieve less leakage, improve delivery, and improve therapeutic effects

Active Publication Date: 2022-02-25
NANJING MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007]However, many neuroprotective agents have shown good neurorestorative effects in vitro, but the results of in vivo or clinical trials are often disappointing. The main reason is that the blood brain the presence of barriers
Moreover, the NF-κB signaling pathway exists not only in the constituent cells of the "neurovascular unit", but also in almost all mammalian cells. Non-selective inhibition of the NF-κB signaling pathway may lead to severe immunosuppressive diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RNS-response-based 'nervous vascular unit' regulation and control targeted liposome drug delivery system and preparation method and application thereof
  • RNS-response-based 'nervous vascular unit' regulation and control targeted liposome drug delivery system and preparation method and application thereof
  • RNS-response-based 'nervous vascular unit' regulation and control targeted liposome drug delivery system and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1) Preparation of N-(2-aminophenyl)tetradecamide:

[0040] Myristic acid (10mmoL) was dissolved in tetrahydrofuran (150mL), placed in a round bottom flask, and then added 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate ( HCTU) (12mmoL) was stirred for 10 minutes; o-phenylenediamine (10mmoL) was dissolved in acetonitrile (10mL), and the above solution was added and stirred for 15min; triisopropanolamine (30mmoL) was added, and the mixture was stirred overnight at room temperature to Make sure to react completely. The organic solvent was removed by rotary evaporation, and the crude product was purified by chromatography using ethyl acetate:petroleum ether (2:1) as the eluent after extraction.

[0041] Wherein, the structural formula of N-(2-aminophenyl)tetradecamide recorded by nuclear magnetic resonance spectrum is:

[0042] 1 H NMR (400MHz, DMSO-d 6 ,δ):δ:0.795-0.835(t,3H,CO(CH 2 ) 12 CH 3 ),1.162-1.270(m,20H,Ar-COCH 2 CH 2 (CH 2 ) 10 CH ...

Embodiment 2

[0048]Example 2 The "neurovascular unit" based on RNS response regulates the in vitro release of targeted liposome drug delivery system

[0049] The dialysis method was used to investigate the in vitro release behavior of coumarin-6 in the liposome drug delivery system, wherein the liposome preparation method encapsulating coumarin-6 was carried out according to Example 1. In this release experiment, the concentration in the medium after the complete release of coumarin-6 was designed to be 20 μg / mL to ensure that the drug release was carried out in a sink state. The release media were saturated NO solution prepared in phosphate buffer (pH=7.4) containing 0.5% Tween-80 and phosphate buffer (pH=7.4) containing 0.5% Tween-80, respectively, and the R-Lipo - Put 2mL of C6 solution in a pre-expanded dialysis bag (MWCO=2.50kDa), tie the bag tightly, put it into a 50mL EP tube containing 25mL release medium, and release it in a constant temperature shaking box (37°C, 150rpm) In the ...

Embodiment 3

[0055] In vitro BBB permeability investigation of targeted liposome drug delivery system based on RNS response regulation of "neurovascular unit"

[0056] First establish the Transwell monolayer cell model: bEnd.3 cells in 5×10 4 Cells / well density were seeded in Transwell cell culture chambers (pore size 1.0 μm, surface area 0.33 cm 2 ), placed in a 24-well plate for routine culture for 3 days, when the cell confluence reached 90%, the culture solution was discarded, and the upper and lower chambers were replaced with 10 3 Nmol / L hydrocortisone in DMEM culture solution, cultivated for 3 days, to make the cell junction proteins compact and form a dense monolayer. Aspirate and discard the culture medium in the Transwell chamber, and establish the oxygen-glucose deprivation culture model (Oxygen-glucose deprivation, OGD) of bEnd.3 cells, that is, after washing with PBS, replace with sugar-free medium and culture in a tri-gas incubator for 12 hours, and then replace with The co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses an RNS-response-based 'nervous vascular unit' regulation and control targeted liposome drug delivery system and a preparation method and application thereof. The targeted drug delivery system is formed by hydrogenated soybean phospholipid (HSPC), cholesterol, c (RGDyK) grafted PEGylated phospholipid c (RGDyK)-PEG2000-DSPE and a neuroprotective agent caffeic acid phenethyl ester entrapped by lipid micromolecules with RNS responsiveness, wherein the lipid micromolecules with RNS responsiveness are prepared through an acid-base condensation reaction of o-phenylenediamine and tetradecanoic acid. The carrier system has the characteristics of good biocompatibility, capability of effectively prolonging in-vivo circulation time and the like, can be targeted to a cerebral ischemic stroke lesion part through the c (RGDyK) peptide, and responds to RNS accumulated in an ischemia reperfusion focus to release phenethyl caffeate, so that the drug is quickly released at the cerebral ischemia lesion part, and by remodeling the 'nerve vascular unit', the treatment effect on cerebral arterial thrombosis is enhanced, and toxic and side effects are reduced.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to an RNS response-based cerebral ischemia-reperfusion targeting liposome drug delivery system, a preparation method thereof, and an application in anti-ischemic stroke. Background technique [0002] With the aging of the population and the deterioration of the ecological environment, the incidence of brain diseases is increasing year by year, becoming a major disease that endangers human life and health. Among them, stroke is a cerebrovascular and blood circulation disorder disease with high morbidity, high mortality, high disability, and high recurrence rate. Leading cause of death and third leading cause of potential loss of life in the world. In my country, the number of new patients is as high as 5.5 million every year, and there are 13 million stroke patients who are living with the disease. If the prognosis of the patients is not ideal, it will seriously affec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/64A61K47/60A61K47/54A61K47/69A61K31/216A61P9/10C07C231/02C07C231/24C07C233/43
CPCA61K47/64A61K47/60A61K47/544A61K47/554A61K47/54A61K47/6911A61K31/216A61P9/10C07C231/02C07C231/24C07C233/43
Inventor 辛洪亮陆红丹叶璐李胜男滕传慧孙善波
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap